Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

A Study of ELVN-001 Versus Investigator-Selected TKI, in CP-CML Previously Treated With One or More TKIs (ENABLE-2)

13 de noviembre de 2026 actualizado por: Enliven Therapeutics

A Phase 3, Multicenter, Open-Label, Randomized Study of ELVN-001 Versus Investigator-Selected Tyrosine Kinase Inhibitor (TKI) of Dasatinib, Nilotinib, or Bosutinib, in Adult Participants With Chronic Myeloid Leukemia in Chronic Phase (CP-CML), Previously Treated With One or More TKIs

The study is designed to compare the efficacy of ELVN-001 versus Investigator-selected tyrosine kinase inhibitor (TKI) for adults with previously treated chronic myeloid leukemia in the chronic phase (CP-CML). The Investigator-selected TKI will be one of the following standard of care therapies: Dasatinib, Nilotinib, or Bosutinib.

Descripción general del estudio

Estado

Reclutamiento

Condiciones

Intervención / Tratamiento

Descripción detallada

This is a multicenter, open-label, randomized study of ELVN-001 versus Investigator-selected TKI (Dasatinib, Nilotinib, or Bosutinib) in adult participants with CP-CML previously treated with one or more TKIs. Participants will be randomized to receive either ELVN-001 or their investigator's choice of one of the comparator TKIs (Dasatinib, Nilotinib, or Bosutinib). Treatment will continue until one of the protocol defined treatment discontinuation criteria are met. Participants will then enter a long-term follow-up period for survivorship and updates on disease status.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

450

Fase

  • Fase 3

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

    • Georgia
      • Atlanta, Georgia, Estados Unidos, 30322
        • Reclutamiento
        • Winship Cancer Institute
    • Indiana
      • Indianapolis, Indiana, Estados Unidos, 46260
        • Reclutamiento
        • Investigative Clinical Research of Indiana, LLC
    • New Jersey
      • Morristown, New Jersey, Estados Unidos, 07960
        • Reclutamiento
        • Atlantic Health System
    • Utah
      • Ogden, Utah, Estados Unidos, 84405
        • Reclutamiento
        • Community Center Trials of Utah

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Male or female at least 18 years of age
  • Diagnosis of chronic myeloid leukemia in chronic phase (CP-CML)
  • Prior treatment with 1 or more BCR::ABL1 TKI(s)
  • Failure or intolerance on the immediate prior TKI
  • Adequate end organ function as measured by blood tests

Exclusion Criteria:

  • Known T315I mutation
  • Known second chronic phase of CML after previous progression to accelerated or blast phase
  • Any serious or uncontrolled medical disorder
  • QT interval corrected by Fridericia's formula (QTcF) ≥ 470 msec
  • Previous treatment with a hematopoietic stem-cell transplantation

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: ELVN-001

ELVN-001

ELVN-001 orally daily

Comparador activo: Investigator-selected TKI

Randomized to receive one of the following investigator's choice TKIs: Dasatinib, Nilotinib, or Bosutinib

TKI orally daily

Otros nombres:
  • Dasatinib
  • Nilotinib
  • Bosutinib

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Major Molecular Response (MMR) Rate at Week 24 - ELVN-001 versus Investigator-selected TKI
Periodo de tiempo: 24 weeks

Molecular response is assessed using BCR::ABL1 transcript levels measured by quantitative polymerase chain reaction (qPCR). MMR is defined as a ratio BCR::ABL/ABL1 ≤ 0.1% on the International Scale.

24 weeks

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Major Molecular Response (MMR) Rate at Week 96 - ELVN-001 versus Investigator-selected TKI
Periodo de tiempo: 96 weeks

Molecular response is assessed using BCR::ABL1 transcript levels measured by quantitative polymerase chain reaction (qPCR). MMR is defined as a ratio BCR::ABL/ABL1 ≤ 0.1% on the International Scale.

96 weeks
Change in overall scores, individual scales, and health status based on participant reporting - ELVN-001 versus Investigator-selected TKI
Periodo de tiempo: planned total follow-up duration of 5 years

Validated questionnaires will be used to assess disease-related symptoms, functioning, and tolerability.

planned total follow-up duration of 5 years
Major Molecular Response (MMR) at all scheduled collection time points - ELVN-001 versus Investigator-selected TKI
Periodo de tiempo: planned total follow-up duration of 5 years

Molecular response is assessed using BCR::ABL1 transcript levels measured by quantitative polymerase chain reaction (qPCR). MMR is defined as a ratio BCR::ABL/ABL1 ≤ 0.1% on the International Scale

planned total follow-up duration of 5 years
Major Molecular Response (MMR) by all scheduled collection time points - ELVN-001 versus Investigator-selected TKI
Periodo de tiempo: planned total follow-up duration of 5 years

Molecular response is assessed using BCR::ABL1 transcript levels measured by quantitative polymerase chain reaction (qPCR). MMR is defined as a ratio BCR::ABL/ABL1 ≤ 0.1% on the International Scale

planned total follow-up duration of 5 years
Time to Major Molecular Response (MMR) - ELVN-001 versus Investigator-selected TKI
Periodo de tiempo: planned total follow-up duration of 5 years

The time to MMR is defined as the time from the date of randomization to the date of the first documented occurrence of MMR

planned total follow-up duration of 5 years
Duration of Major Molecular Response (MMR) - ELVN-001 versus Investigator-selected TKI
Periodo de tiempo: planned total follow-up duration of 5 years

Duration of MMR is defined as the time between the date of the first achievement of MMR and the earliest date of loss of MMR or CML-related death

planned total follow-up duration of 5 years
BCR::ABL1 ratio ≤ 1% at and by all scheduled data collection time points - ELVN-001 versus Investigator-selected TKI
Periodo de tiempo: planned total follow-up duration of 5 years

BCR::ABL1 transcript levels are measured by quantitative polymerase chain reaction (qPCR). The ratio is calculated for BCR::ABL/ABL1 based on the International Scale

planned total follow-up duration of 5 years
Time to treatment failure - ELVN-001 versus Investigator-selected TKI
Periodo de tiempo: planned total follow-up duration of 5 years

Time to treatment failure is defined as the time from randomization to the first date of any of the following events: treatment failure as defined per protocol

planned total follow-up duration of 5 years
Progression-free survival - ELVN-001 versus Investigator-selected TKI
Periodo de tiempo: planned total follow-up duration of 5 years

Progression-free survival is defined as the time from randomization to the earliest occurrence of progression or death from any cause

planned total follow-up duration of 5 years
Overall survival (OS) - ELVN-001 versus Investigator-selected TKI
Periodo de tiempo: planned total follow-up duration of 5 years

OS is defined as the time from randomization to death from any cause

planned total follow-up duration of 5 years
MR4 and MR4.5 at and by all scheduled data collection time points - ELVN-001 versus Investigator-selected TKI
Periodo de tiempo: planned total follow-up duration of 5 years

Molecular response is assessed using BCR::ABL1 transcript levels measured by quantitative polymerase chain reaction (qPCR). MR4 is defined as a ratio BCR::ABL/ABL1 ≤ 0.01% on the International Scale and MR4.5 is defined as a ratio BCR::ABL/ABL1 ≤ 0.0032% on the International Scale

planned total follow-up duration of 5 years
Time to treatment discontinuation due to adverse event (AE) - ELVN-001 versus Investigator-selected TKI
Periodo de tiempo: planned total follow-up duration of 5 years

This is defined as the time from randomization to discontinuation of study treatment due to an adverse event

planned total follow-up duration of 5 years
Characterization of adverse events (AE) and clinically relevant findings, including laboratory abnormalities, electrocardiogram (ECG) changes, and other safety data - ELVN-001 versus Investigator-selected TKI
Periodo de tiempo: planned total follow-up duration of 5 years

Characteristics of AEs will be evaluated to assess safety and tolerability profiles

planned total follow-up duration of 5 years
Plasma concentrations of ELVN-001 in participants treated with ELVN-001 will be assessed at all scheduled collection timepoints
Periodo de tiempo: planned total follow-up duration of 5 years

Relevant pharmacokinetic parameters will be evaluated

planned total follow-up duration of 5 years

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

31 de diciembre de 2026

Finalización primaria (Estimado)

31 de diciembre de 2028

Finalización del estudio (Estimado)

1 de julio de 2033

Fechas de registro del estudio

Enviado por primera vez

23 de octubre de 2026

Primero enviado que cumplió con los criterios de control de calidad

23 de octubre de 2026

Publicado por primera vez (Actual)

29 de octubre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

18 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

13 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • ELVN-001-301
  • 2026-526266-25-00 (Ctis)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .